Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock, par value $0.0001
-
Shares outstanding
-
53M
-
Number of holders
-
110
-
Total 13F shares, excl. options
-
28M
-
Shares change
-
+609K
-
Total reported value, excl. options
-
$463M
-
Value change
-
+$17.7M
-
Put/Call ratio
-
0.94
-
Number of buys
-
54
-
Number of sells
-
-50
-
Price
-
$16.50
Significant Holders of Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) as of Q3 2023
139 filings reported holding CDLX - Cardlytics, Inc. - Common Stock, par value $0.0001 as of Q3 2023.
Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) has 110 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28M shares
of 53M outstanding shares and own 52.87% of the company stock.
Largest 10 shareholders include CAS Investment Partners, LLC (5.42M shares), BlackRock Inc. (2.65M shares), VANGUARD GROUP INC (2.01M shares), 683 Capital Management, LLC (1.76M shares), KPS Global Asset Management UK Ltd (1.22M shares), MARSHALL WACE, LLP (1.05M shares), BAILLIE GIFFORD & CO (1.05M shares), WORLDLY PARTNERS MANAGEMENT, LLC (997K shares), Invesco Ltd. (803K shares), and GEODE CAPITAL MANAGEMENT, LLC (744K shares).
This table shows the top 110 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.